Abbott Laboratories $ABT Shares Acquired by Vestcor Inc

Vestcor Inc boosted its holdings in Abbott Laboratories (NYSE:ABT) by 46.6% in the 4th quarter, Holdings Channel reports. The firm owned 112,714 shares of the healthcare product maker’s stock after purchasing an additional 35,849 shares during the period. Vestcor Inc’s holdings in Abbott Laboratories were worth $14,122,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of ABT. Vanguard Group Inc. boosted its stake in shares of Abbott Laboratories by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after buying an additional 2,402,408 shares during the period. Capital International Investors increased its position in Abbott Laboratories by 2.5% in the 3rd quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock valued at $8,251,974,000 after acquiring an additional 1,478,076 shares during the period. Norges Bank purchased a new stake in Abbott Laboratories during the 4th quarter valued at approximately $2,938,892,000. Invesco Ltd. lifted its position in Abbott Laboratories by 51.0% during the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after acquiring an additional 4,713,135 shares during the period. Finally, Ameriprise Financial Inc. lifted its position in Abbott Laboratories by 3.8% during the 3rd quarter. Ameriprise Financial Inc. now owns 13,500,829 shares of the healthcare product maker’s stock worth $1,804,050,000 after acquiring an additional 499,351 shares during the period. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Philip P. Boudreau purchased 2,200 shares of the stock in a transaction that occurred on Thursday, April 23rd. The stock was purchased at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.46% of the company’s stock.

Wall Street Analysts Forecast Growth

ABT has been the subject of several analyst reports. Oppenheimer cut their price target on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Mizuho dropped their price objective on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. Wells Fargo & Company cut their price objective on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Barclays lowered their target price on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a report on Monday, April 20th. Finally, BTIG Research reiterated a “buy” rating and set a $131.00 price target on shares of Abbott Laboratories in a research note on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $119.09.

Abbott Laboratories Trading Up 0.5%

NYSE:ABT opened at $91.20 on Friday. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $139.06. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The stock has a fifty day moving average price of $92.80 and a two-hundred day moving average price of $109.31. The stock has a market capitalization of $158.85 billion, a price-to-earnings ratio of 25.55, a PEG ratio of 1.51 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business’s revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.